Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Prizes
Spin-Offs
Media
Activities
Datasets
Search by expertise, name or affiliation
The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction
Patrick Terheyden
*
, Angela Krackhardt, Thomas Eigentler
*
Corresponding author for this work
Clinic of Dermatology, Allergology and Venerology
Technical University of Munich
University of Tubingen
27
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The Systemic Treatment of Melanoma: The Place of Immune Checkpoint Inhibitors and the Suppression of Intracellular Signal Transduction'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Systemic Therapy
100%
Melanoma
100%
Immune Checkpoint Inhibitor
100%
Overall Survival
75%
Hazard Ratio
75%
MEK Inhibitor
50%
Recurrent Disease
25%
Immunity
25%
Brain Metastasis
25%
T Cell
25%
Metastatic Melanoma
25%
Death Receptor
25%
Dacarbazine
25%
Pembrolizumab
25%
Nivolumab
25%
Cytotoxic T-Cell
25%
Metastasectomy
25%
Immunocompetent Cell
25%
Monotherapy
25%
Melanoma Cell
25%
CTLA-4
25%
Pharmacology, Toxicology and Pharmaceutical Science
Melanoma
100%
Systemic Treatment
100%
Immune Checkpoint Inhibitor
100%
Overall Survival
60%
Mitogen Activated Protein Kinase Kinase Inhibitor
40%
Monotherapy
20%
Recurrent Disease
20%
Death Receptor
20%
Brain Metastasis
20%
Pembrolizumab
20%
Cytotoxic T Lymphocyte Antigen 4
20%